MedTrace Logo

Efficacy and Safety of Four Escalating Dose Regimens of TPI ASM8 in Patients With Allergic Asthma

NCT00822861 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2013-11-15

No results posted yet for this study

Summary

During this proposed clinical trial, the investigators intend to evaluate the pharmacodynamic anti-inflammatory properties and safety of TPI ASM8, by investigating the effect on sputum eosinophils and the airway responses during an allergen challenge at different dose levels.

Conditions

Interventions

DRUG

TPI ASM8

4 mg/mL, 1 mg BID for 4 days

DRUG

TPI ASM8

4 mg/mL, 2 mg BID for 4 days

DRUG

TPI ASM8

4 mg/mL, 4 mg BID for 4 days

DRUG

TPI ASM8

4 mg/mL, 8 mg OD for 4 days

Sponsors & Collaborators

  • Syntara

    lead INDUSTRY

Principal Investigators

  • Rene Pageau, B.Pharm M.Sc · Topigen Pharmaceuticals Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00822861 on ClinicalTrials.gov